This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Mebeverine hydrochloride mr cap 200mg

Updated 2 Feb 2023 | Other antispasmodics


Modified release capsules containing mebeverine hydrochloride.

Drugs List

  • AUROBEVERINE MR 200mg modified release capsules
  • COLOFAC MR 200mg modified release capsules
  • mebeverine 200mg modified release capsules
  • Therapeutic Indications


    Irritable bowel syndrome



    200mg twice a day (morning and evening).


    Children aged over 10 years
    200mg twice a day (morning and evening).


    Children under 10 years
    Paralytic ileus

    Precautions and Warnings

    Glucose-galactose malabsorption syndrome
    Hereditary fructose intolerance

    Not all available brands are licensed for all age groups
    Some formulations contain sucrose

    Pregnancy and Lactation


    Mebeverine hydrochloride should be used with caution in pregnancy.

    There have been no detailed studies on the use of mebeverine during pregnancy. Animal studies are insufficient with respect to reproductive toxicity.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Mebeverine hydrochloride should be used with caution during breastfeeding.

    There is a small risk that suppression of milk production could occur with anticholinergic drugs, although there is no published evidence to support this (UK Drugs in Lactation Advisory Service).

    It is unknown whether mebeverine is excreted in human milk. The excretion of mebeverine in milk has not been studied in animals.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Allergic reaction
    Anaphylactic reaction
    Facial oedema
    Hypersensitivity reactions


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: March 2018

    Reference Sources

    Summary of Product Characteristics: Aurobeverine MR 200 mg modified-release capsules, hard. Milpharm Limited. Revised April 2017.

    Summary of Product Characteristics: Colofac MR. Mylan Products Limited. Revised August 2016.

    NICE Evidence Services Available at: Last accessed: 20 March 2018

    UK Drugs in Lactation Advisory Service.
    Available at:
    Last accessed: 20 March 2018

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.